Frdric Calon

List of Publications by Citations

160 papers	9,588 citations	57 h-index	94 g-index
176 ext. papers	10,734 ext. citations	6.1 avg, IF	5.92 L-index

#	Paper	IF	Citations
160	Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. *Neuron*, **2004**, 43, 633-45	13.9	602
159	A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. *Journal of Neuroscience*, **2005**, 25, 3032-40	6.6	555
158	Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 48-58	3.1	299
157	Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. *Nature Neuroscience*, **2006**, 9, 234-42	25.5	262
156	Novel pharmacological targets for the treatment of Parkinson's disease. *Nature Reviews Drug Discovery*, **2006**, 5, 845-54	64.1	229
155	High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. *Neurobiology of Aging*, **2010**, 31, 1516-31	5.6	208
154	Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. *European Journal of Neuroscience*, **2005**, 22, 617-26	3.5	198
153	Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2007**, 77, 287-93	2.8	192
152	Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. *Neurobiology of Disease*, **2003**, 14, 404-16	7.5	186
151	Synthesis of pegylated immunonanoparticles. *Pharmaceutical Research*, **2002**, 19, 1137-43	4.5	178
150	Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. *Human Gene Therapy*, **2003**, 14, 1-12	4.8	176
149	Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR□mediated mechanisms in Alzheimer's disease models. *PLoS ONE*, **2011**, 6, e15816	3.7	174
148	Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. *FASEB Journal*, **2008**, 22, 1213-25	0.9	171
147	Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. *Brain*, **2004**, 127, 1075-84	11.2	162
146	Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. *Neurochemistry International*, **2009**, 55, 476-82	4.4	157
145	Insulin reverses the high-fat diet-induced increase in brain A□and improves memory in an animal model of Alzheimer disease. *Diabetes*, **2014**, 63, 4291-301	0.9	150
144	Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. *Annals of Neurology*, **2015**, 78, 160-77	9.4	146

143	Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease. *Cell Stem Cell*, **2015**, 17, 397-411	18	127
142	DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. *PLoS ONE*, **2011**, 6, e17397	3.7	125
141	miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. *Human Molecular Genetics*, **2015**, 24, 6721-35	5.6	124
140	Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. *Progress in Neurobiology*, **2007**, 83, 293-309	10.9	123
139	Defective dentate nucleus GABA receptors in essential tremor. *Brain*, **2012**, 135, 105-16	11.2	119
138	Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2009**, 80, 157-63	2.8	117
137	mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. *Neurobiology of Aging*, **2008**, 29, 1040-51	5.6	114
136	Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 186-96	3.1	107
135	Human apolipoprotein E e4 expression impairs cerebral vascularization and blood-brain barrier function in mice. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 86-94	7.3	102
134	Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). *Behavioural Brain Research*, **2012**, 234, 334-42	3.4	102
133	Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. *Biological Psychiatry*, **2001** , 50, 813-6	7.9	100
132	Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. *Current Pharmaceutical Design*, **2000**, 6, 1287-312	3.3	97
131	Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. *Brain Research*, **1995**, 680, 43-52	3.7	96
130	Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. *Journal of Pharmacology and Experimental Therapeutics*, **1995**, 272, 854-9	4.7	95
129	Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. *Molecular Brain Research*, **1997**, 49, 55-62		94
128	p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. *Journal of Biological Chemistry*, **2008**, 283, 14132-43	5.4	94
127	A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease. *Biological Psychiatry*, **2018**, 83, 395-405	7.9	94
126	Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 1983-92	7.3	93

125	Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function. *Molecular Neurodegeneration*, **2011**, 6, 70	19	89
124	Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer's disease. *European Journal of Neuroscience*, **2010**, 32, 905-20	3.5	87
123	Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. *Neurochemistry International*, **2006**, 48, 404-14	4.4	87
122	Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. *Movement Disorders*, **2003**, 18, 241-253	7	86
121	Impact of B fatty acids in Parkinson's disease. *Ageing Research Reviews*, **2011**, 10, 453-63	12	80
120	ABCG2- and ABCG4-mediated efflux of amyloid- peptide 1-40 at the mouse blood-brain barrier. *Journal of Alzheimer's Disease*, **2012**, 30, 155-66	4.3	79
119	n-3 LCPUFA improves cognition: the young, the old and the sick. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2014**, 91, 1-20	2.8	78
118	Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. *Neuropharmacology*, **2009**, 56, 808-13	5.5	78
117	Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions. *PLoS ONE*, **2014**, 9, e94251	3.7	77
116	Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 1401-8	5.5	77
115	Molecular basis of levodopa-induced dyskinesias. *Annals of Neurology*, **2000**, 47, S70-8	9.4	76
114	Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2002**, 26, 127-38	5.5	74
113	Dopamine-receptor stimulation: biobehavioral and biochemical consequences. *Trends in Neurosciences*, **2000**, 23, S92-100	13.3	70
112	microRNA-132/212 deficiency enhances A production and senile plaque deposition in Alzheimer's disease triple transgenic mice. *Scientific Reports*, **2016**, 6, 30953	4.9	66
111	Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage. *Stroke*, **2011**, 42, 2903-9	6.7	66
110	Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. *Journal of Neurochemistry*, **2014**, 129, 516-26	6	65
109	Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease. *FASEB Journal*, **2015**, 29, 4273-84	0.9	62
108	High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. *Neurobiology of Disease*, **2012**, 45, 529-38	7.5	59

107	Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. *Movement Disorders*, **2006**, 21, 9-17	7	59
106	In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. *Molecular Pharmacology*, **2011**, 80, 32-9	4.3	58
105	Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. *Journal of Alzheimer's Disease*, **2007**, 12, 377-90	4.3	58
104	The benefit of docosahexaenoic acid for the adult brain in aging and dementia. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2015**, 92, 15-22	2.8	57
103	Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease. *Journal of Lipid Research*, **2011**, 52, 263-71	6.3	56
102	Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers. *Current Alzheimer Research*, **2011**, 8, 470-8	3	55
101	Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease. *Journal of Alzheimer's Disease*, **2011**, 27, 853-69	4.3	54
100	Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 788-98	3.1	53
99	Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. *Parkinsonism and Related Disorders*, **2004**, 10, 297-304	3.6	53
98	IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and A pathology. *Journal of Neuroinflammation*, **2014**, 11, 54	10.1	51
97	Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease. *Neuropharmacology*, **2014**, 81, 311-7	5.5	50
96	High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease. *Neuroscience*, **2009**, 159, 296-307	3.9	45
95	Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. *Neuropharmacology*, **2008**, 54, 258-68	5.5	45
94	Novel liposomal formulation for targeted gene delivery. *Pharmaceutical Research*, **2007**, 24, 981-90	4.5	43
93	Sex-dependent alterations in social behaviour and cortical synaptic activity coincide at different ages in a model of Alzheimer's disease. *PLoS ONE*, **2012**, 7, e46111	3.7	42
92	Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content. *Neurochemistry International*, **1999**, 35, 81-91	4.4	41
91	Polyphenol-rich extract from grape and blueberry attenuates cognitive decline and improves neuronal function in aged mice. *Journal of Nutritional Science*, **2018**, 7, e19	2.7	40
90	Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. *Synapse*, **2006**, 60, 239-50	2.4	39

89	Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-□ Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD). *Journal of Alzheimer's Disease*, **2016**, 49, 287-300	4.3	38
88	Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. *Journal of Neurochemistry*, **2010**, 114, 1651-8	6	38
87	Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. *Neuroscience*, **1997**, 79, 497-507	3.9	36
86	Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer's disease. *Acta Neuropathologica*, **2019**, 137, 801-823	14.3	35
85	Increased LINGO1 in the cerebellum of essential tremor patients. *Movement Disorders*, **2014**, 29, 1637-47	7	35
84	Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. *Journal of Neuroscience Research*, **2008**, 86, 2292-302	4.4	35
83	Transferrin Receptor-Mediated Uptake at the Blood-Brain Barrier Is Not Impaired by Alzheimer's Disease Neuropathology. *Molecular Pharmaceutics*, **2019**, 16, 583-594	5.6	35
82	Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. *Molecular Pharmacology*, **1996**, 50, 1073-9	4.3	34
81	Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 55, 115-135	4.3	33
80	Internalization of targeted quantum dots by brain capillary endothelial cells in vivo. *Journal of Cerebral Blood Flow and Metabolism*, **2016**, 36, 731-42	7.3	32
79	125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. *Experimental Neurology*, **2000**, 163, 191-9	5.7	32
78	Impaired thermoregulation and beneficial effects of thermoneutrality in the 3□g-AD model of Alzheimer's disease. *Neurobiology of Aging*, **2016**, 43, 47-57	5.6	32
77	Antibody-conjugated mesoporous silica nanoparticles for brain microvessel endothelial cell targeting. *Journal of Materials Chemistry B*, **2017**, 5, 7721-7735	7.3	31
76	Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain. *Parkinsonism and Related Disorders*, **2002**, 8, 449-54	3.6	31
75	eEF2K inhibition blocks A□2 neurotoxicity by promoting an NRF2 antioxidant response. *Acta Neuropathologica*, **2017**, 133, 101-119	14.3	30
74	Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter. *Synapse*, **2001**, 40, 225-34	2.4	30
73	Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer's disease. *Neurobiology of Disease*, **2017**, 98, 1-8	7.5	29
72	Hypothermia mediates age-dependent increase of tau phosphorylation in db/db mice. *Neurobiology of Disease*, **2016**, 88, 55-65	7.5	28

71	Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 193-203	5.5	28
70	PAK inactivation impairs social recognition in 3xTg-AD Mice without increasing brain deposition of tau and A *Journal of Neuroscience*, **2013**, 33, 10729-40	6.6	27
69	The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. *Journal of Neuroinflammation*, **2011**, 8, 137	10.1	27
68	Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion. *Molecular Pharmaceutics*, **2014**, 11, 243-53	5.6	26
67	Metabotropic glutamate receptor II in the brains of Parkinsonian patients. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 374-82	3.1	26
66	Omega-3 polyunsaturated fatty acids and brain health: Preclinical evidence for the prevention of neurodegenerative diseases. *Trends in Food Science and Technology*, **2017**, 69, 203-213	15.3	25
65	Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?. *Acta Neuropathologica*, **2016**, 131, 481-504	14.3	25
64	Dietary intake of branched-chain amino acids in a mouse model of Alzheimer's disease: Effects on survival, behavior, and neuropathology. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 677-687	6	24
63	Old age potentiates cold-induced tau phosphorylation: linking thermoregulatory deficit with Alzheimer's disease. *Neurobiology of Aging*, **2017**, 50, 25-29	5.6	22
62	Direct evidence of abca1-mediated efflux of cholesterol at the mouse blood-brain barrier. *Molecular and Cellular Biochemistry*, **2011**, 357, 397-404	4.2	22
61	L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. *Journal of Chemical Neuroanatomy*, **2008**, 35, 77-84	3.2	22
60	Protective effects of berry polyphenols against age-related cognitive impairment. *Nutrition and Aging (Amsterdam, Netherlands)*, **2016**, 3, 89-106		22
59	Age-related deregulation of TDP-43 after stroke enhances NF- B-mediated inflammation and neuronal damage. *Journal of Neuroinflammation*, **2018**, 15, 312	10.1	22
58	Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease. *Journal of Neuroinflammation*, **2019**, 16, 3	10.1	21
57	and Parkinson's Disease. *Frontiers in Neurology*, **2019**, 10, 758	4.1	20
56	Can insulin signaling pathways be targeted to transport A but of the brain?. *Frontiers in Aging Neuroscience*, **2015**, 7, 114	5.3	20
55	Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system. *Journal of Nutritional Biochemistry*, **2016**, 30, 133-42	6.3	20
54	Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 70-88	3.1	19

53	High-fat, high-sugar, and high-cholesterol consumption does not impact tau pathogenesis in a mouse model of Alzheimer's disease-like tau pathology. *Neurobiology of Aging*, **2016**, 47, 71-73	5.6	18
52	Repeated cold exposures protect a mouse model of Alzheimer's disease against cold-induced tau phosphorylation. *Molecular Metabolism*, **2019**, 22, 110-120	8.8	16
51	Potentiation of the bioavailability of blueberry phenolic compounds by co-ingested grape phenolic compounds in mice, revealed by targeted metabolomic profiling in plasma and feces. *Food and Function*, **2016**, 7, 3421-30	6.1	16
50	Spray and freeze drying of human milk on the retention of immunoglobulins (IgA, IgG, IgM). *Drying Technology*, **2016**, 34, 1801-1809	2.6	16
49	Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology. *Neuropathology and Applied Neurobiology*, **2020**, 46, 458-477	5.2	15
48	Dietary intake of unsaturated fatty acids modulates physiological properties of entorhinal cortex neurons in mice. *Journal of Neurochemistry*, **2012**, 122, 427-43	6	15
47	Apolipoprotein E isoforms disrupt long-chain fatty acid distribution in the plasma, the liver and the adipose tissue of mice. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2014**, 91, 261-7	2.8	14
46	Impact of DHA intake in a mouse model of synucleinopathy. *Experimental Neurology*, **2018**, 301, 39-49	5.7	13
45	Chronic dietary intake of □inolenic acid does not replicate the effects of DHA on passive properties of entorhinal cortex neurons. *British Journal of Nutrition*, **2012**, 107, 1099-111	3.6	13
44	Neuroligin-1 is altered in the hippocampus of Alzheimer's disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers. *Scientific Reports*, **2020**, 10, 6956	4.9	12
43	Transgenic autoinhibition of p21-activated kinase exacerbates synaptic impairments and fronto-dependent behavioral deficits in an animal model of Alzheimer's disease. *Aging*, **2017**, 9, 1386-1403	5.6	12
42	Interaction of transactive response DNA binding protein 43 with nuclear factor B in mild cognitive impairment with episodic memory deficits. *Acta Neuropathologica Communications*, **2014**, 2, 37	7.3	12
41	Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. *Neuroscience*, **2017**, 361, 43-57	3.9	12
40	Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. *Journal of Neuroinflammation*, **2012**, 9, 234	10.1	12
39	Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys. *Synapse*, **2008**, 62, 101-9	2.4	11
38	Docosahexaenoic acid prevents cognitive deficits in human apolipoprotein E epsilon 4-targeted replacement mice. *Neurobiology of Aging*, **2017**, 57, 28-35	5.6	10
37	N-3 polyunsaturated fatty acid and neuroinflammation in aging and Alzheimer□ disease. *Nutrition and Aging (Amsterdam, Netherlands)*, **2015**, 3, 33-47		10
36	Accumulation of amyloid-□n the cerebellar cortex of essential tremor patients. *Neurobiology of Disease*, **2015**, 82, 397-408	7.5	9

35	Characterization of a 3xTg-AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background. *Synapse*, **2018**, 72, e22025	2.4	9
34	Can we prevent Parkinson disease with n-3 polyunsaturated fatty acids?. *Future Lipidology*, **2008**, 3, 133-137		9
33	Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease. *Neurochemistry International*, **2020**, 141, 104881	4.4	9
32	Nonpatentable drugs and the cost of our ignorance. *Cmaj*, **2006**, 174, 483-4	3.5	8
31	The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q). *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 787-796	5.2	8
30	Altered cerebral insulin response in transgenic mice expressing the epsilon-4 allele of the human apolipoprotein E gene. *Psychoneuroendocrinology*, **2017**, 77, 203-210	5	7
29	The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. *European Journal of Neuroscience*, **2014**, 40, 2406-16	3.5	7
28	Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry. *Current Neuropharmacology*, **2021**, 19, 591-609	7.6	7
27	Can Natural Products Exert Neuroprotection without Crossing the Blood-Brain Barrier?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
26	Tetrahydrobiopterin administration facilitates amphetamine-induced dopamine release and motivation in mice. *Behavioural Brain Research*, **2020**, 379, 112348	3.4	5
25	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. *Ageing Research Reviews*, **2021**, 72, 101462	12	5
24	New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. *BMC Neuroscience*, **2012**, 13, 84	3.2	4
23	Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17 hydroxysteroid dehydrogenase type 10. *Bioorganic and Medicinal Chemistry Letters* , **2018**, 28, 3554-3559	2.9	4
22	THE 3XTG-AD MOUSE MODEL OF ALZHEIMER'S DISEASE EXHIBITS AGE-DEPENDENT IMPAIRED GLUCOSE TOLERANCE **2014**, 10, P305-P305		3
21	Sex-dependent alterations in the physiology of entorhinal cortex neurons in old heterozygous 3xTg-AD mice. *Biology of Sex Differences*, **2020**, 11, 63	9.3	3
20	Repurposing beta-3 adrenergic receptor agonists for Alzheimer's disease: beneficial effects in a mouse model. *Alzheimer's Research and Therapy*, **2021**, 13, 103	9	3
19	Response to Comment on Vandal et al. Insulin Reverses the High-Fat Diet-Induced Increase in Brain A and Improves Memory in an Animal Model of Alzheimer Disease. Diabetes 2014;63:4291-4301. *Diabetes*, **2015**, 64, e18	0.9	2
18	Role of Retinoid X Receptors (RXRs) and dietary vitamin A in Alzheimer's disease: Evidence from clinicopathological and preclinical studies. *Neurobiology of Disease*, **2021**, 161, 105542	7.5	2

17	Targeting TDP-43 Pathology Alleviates Cognitive and Motor Deficits Caused by Chronic Cerebral Hypoperfusion. *Neurotherapeutics*, **2021**, 18, 1095-1112	6.4	2
16	Tetrahydrobiopterin Improves Recognition Memory in the Triple-Transgenic Mouse Model of Alzheimer's Disease, Without Altering Amyloid-□and Tau Pathologies. *Journal of Alzheimer's Disease*, **2021**, 79, 709-727	4.3	2
15	Modulation des lipides du cerveau par l□alimentation´: □udes chez des mod□es animaux de maladies neurod□□□atives. *Cahiers De Nutrition Et De Dietetique*, **2014**, 49, 120-125	0.2	1
14	P4-106: The Pathological Role of TDP-43 and NF-KB in Mild Cognitive Impairment and Alzheimer's Disease **2016**, 12, P1053-P1053		1
13	P1-016: Sustained Effect of Cold Exposure on TAU Phosphorylation: Relevance for Alzheimer□ Disease **2016**, 12, P405-P405		1
12	Strategies in the design and development of (TAR) DNA-binding protein 43 (TDP-43) binding ligands. *European Journal of Medicinal Chemistry*, **2021**, 225, 113753	6.8	1
11	Sauna-like conditions or menthol treatment reduce tau phosphorylation through mild hyperthermia		1
10	High-Fat Diet Modulates Hepatic Amyloid □and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer's Disease. *Hepatology Communications*, **2021**, 5, 446-460	6	1
9	Sauna-like conditions or menthol treatment reduce tau phosphorylation through mild hyperthermia.. *Neurobiology of Aging*, **2022**, 113, 118-130	5.6	1
8	The mTOR Signaling Pathway in Neurodegenerative Diseases **2016**, 85-104		0
7	O1-04-03: Identification of a Novel Lipid-Related Drug Target to Reactivate Adult Neural Stem Cells in Alzheimer's Disease **2016**, 12, P180-P181		
6	P2-394: INSULIN REVERSES THE HIGH FAT DIET-INDUCED INCREASE IN BRAIN A□AND IMPROVES MEMORY IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE **2014**, 10, P623-P623		
5	[P4□62]: EFFECTS OF SPECIFIC NUTRIENTS ON COGNITION AND ALZHEIMER's DISEASE NEUROPATHOLOGY: THE CASE OF BRANCHED-CHAIN AMINO ACIDS (BCAA) **2017**, 13, P1428-P1429		
4	Methods of Regulating Alzheimer Pathogenesis: Diet, Oxidative Damage and Inflammation **2004**, 1-16		
3	P3-078: Altered Cerebral Insulin Response in Transgenic Mice Expressing the Epsilon-4 Allele of the Human Apolipoprotein E Gene **2016**, 12, P848-P848		
2	P3-301: Which Neuropathological Marker Correlates Best with Ante-Mortem Cognitive Symptoms? **2016**, 12, P956-P957		
1	Diet enriched in omega-3 fatty acids alleviates olfactory system deficits in APOE4 transgenic mice. *European Journal of Neuroscience*, **2021**, 54, 7092-7108	3.5	